Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196916 | 0.90 | CA1 (0.64) | CA1CA2NPC1RAB9AMAPT | |
| SCHEMBL69218 | 0.90 | CA1 (0.75) | CA1CA2RAB9AMAPTHPGD | |
| SCHEMBL14367127 | 0.87 | KMT2A (0.69) | CA1CA2NPC1RAB9AMAPT | |
| SCHEMBL14393071 | 0.87 | KMT2A (0.69) | CA1CA2NPC1RAB9AMAPT | |
| SCHEMBL2188276 | 0.84 | CA1 (0.88) | CA1CA2NPC1MAPTTDP1 | |
| SCHEMBL9731450 | 0.84 | CA1 (0.67) | CA1CA2RAB9AMAPTHPGD | |
| SCHEMBL3297101 | 0.84 | HPGD (0.66) | CA1CA2NPC1RAB9AMAPT | |
| SCHEMBL20252722 | 0.84 | CA1 (0.67) | CA1CA2RAB9AMAPTHPGD | |
| SCHEMBL14926631 | 0.84 | CA1 (0.58) | CA1CA2NPC1RAB9AMAPT | |
| SCHEMBL27534852 | 0.83 | NAAA (0.52) | CA1CA2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370771-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| CN-114292260-A | Substituted piperidine multi-target compounds and uses thereof | 华东理工大学 | 2022-04-08 | — | — | CN | disclosed |
| US-20210053935-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-25 | — | — | US | disclosed |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| WO-2019161010-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2914586-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER (US) | 2017-04-05 | — | — | EP | disclosed |
| CN-105008344-A | Bruton's tyrosine kinase inhibitors | PFIZER | 2015-10-28 | — | — | CN | disclosed |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2914586-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Pfizer Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014068527-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | CA1 4470/4885CA2 4037/4885NPC1 4593/4885 |
| US-20150291554-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | CA1 4637/4885CA2 3995/4885NPC1 4594/4885 |
| US-20210053935-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | CA1 3785/4885CA2 265/4885NPC1 159/4885 |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | CA1 4586/4885CA2 3764/4885NPC1 4497/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | CA1 4586/4885CA2 3764/4885NPC1 4497/4885 |
| US-20170283393-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | CA1 4470/4885CA2 4037/4885NPC1 4593/4885 |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, SYK | CA1 4500/4885CA2 3645/4885NPC1 4522/4885 |
| US-11370771-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | CA1 3785/4885CA2 265/4885NPC1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.